Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Padcev/Keytruda Results Could Sweeten Potential Seagen/Merck Deal

Most Observers Still Want More Detailed Data From Urothelial Cancer Study

Executive Summary

Seagen/Astellas announced Phase Ib/II trial data for the combination that could lead to an accelerated approval for the antibody-drug conjugate in first-line bladder cancer.

You may also be interested in...



Japan Q1 Roundup: Enhertu, Padcev, Actemra and Lenvima Push Growth

The main Japanese pharma players report a generally strong fiscal Q1, helped by mainstays including Daiichi Sankyo's Enhertu, Astellas's Xtandi and Padcev and Chugai's Actemra, and in some cases by the weaker yen. 

Seagen Talks Up 24% Growth, Not About Speculated Merck Buyout

The Seattle-based biotech reported a 24% increase in product sales in the second quarter amid speculation that Merck is about to acquire the company.

Merck’s Solid Quarter Doesn’t Soothe Seagen M&A Watchers

Keytruda- and Gardasil-driven revenue growth exceeded forecasts and Merck expects to keep the PD-1 blockbuster cash coming with earlier-stage indications and a potential subcutaneous formulation.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel